- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07520006
Studie zu NX-5948 in Kombination mit anderen Wirkstoffen bei Erwachsenen mit B-Zell-Malignomen
Eine offene, multizentrische Phase-1b/2-Studie zur Bewertung der Sicherheit und Wirksamkeit von NX-5948 in Kombination mit anderen Wirkstoffen bei Erwachsenen mit B-Zell-Malignomen
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Bexobrutideg is an investigational drug designed to target a protein called Bruton tyrosine kinase (BTK), which helps cancer cells grow in certain blood cancers like CLL and SLL. Bexobrutideg is a protein degrader, which means it finds and destroys the BTK in the cell. Venetoclax, rituximab, and obinutuzumab are approved medications that are used to treat CLL/SLL.
The study will look at:
- How safe bexobrutideg is for patients with CLL or SLL when taken with these other treatments
- The effects of bexobrutideg in the body when taken with these other treatments
- How well bexobrutideg treats CLL or SLL when taken with these other treatments
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Additional Site Contact Information
- Telefonnummer: 415-417-3418
- E-Mail: clinicaltrials@nurixtx.com
Studienorte
-
-
California
-
Irvine, California, Vereinigte Staaten, 92618
- Noch keine Rekrutierung
- City of Hope Orange County Lennar Foundation Cancer Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rekrutierung
- Rocky Mountain Cancer Centers
-
-
Florida
-
Coral Gables, Florida, Vereinigte Staaten, 33146
- Noch keine Rekrutierung
- University of Miami
-
-
Kansas
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Noch keine Rekrutierung
- University of Kansas Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89169
- Noch keine Rekrutierung
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Belleville, New Jersey, Vereinigte Staaten, 07109
- Noch keine Rekrutierung
- New Jersey Cancer Care
-
-
Oregon
-
Eugene, Oregon, Vereinigte Staaten, 97401
- Rekrutierung
- Oncology Associates of Oregon
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI Oncology Partners
-
-
Texas
-
Tyler, Texas, Vereinigte Staaten, 75702
- Rekrutierung
- Texas Oncology - Northeast
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ and bone marrow function
- Measurable disease by computed tomography (CT) per iwCLL
- For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
- For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
- Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate
Key Exclusion Criteria:
- Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
- Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
- Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
- Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
- Previously treated with a BTK degrader
- Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
- Known central nervous system (CNS) lymphoma or leukemia
- Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: NX-5948 + Venetoclax
|
Administered orally once daily as a capsule
Andere Namen:
Administered orally once daily as a tablet per prescribing information |
|
Experimental: NX-5948 + Venetoclax + Rituximab
|
Administered orally once daily as a capsule
Andere Namen:
Administered orally once daily as a tablet per prescribing information Administered as an intravenous (IV) infusion per prescribing information |
|
Experimental: NX-5948 + Venetoclax + Obinutuzumab
|
Administered orally once daily as a capsule
Andere Namen:
Administered orally once daily as a tablet per prescribing information Administered as an IV infusion per prescribing information |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Anzahl der Teilnehmer mit therapiebegleitenden unerwünschten Ereignissen
Zeitfenster: Bis zu ungefähr 7 Jahren
|
Bis zu ungefähr 7 Jahren
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective response rate as determined by investigator
Zeitfenster: Up to approximately 7 years
|
The percentage of participants with response as determined according to 2018 iwCLL guidelines; response includes complete response (CR)/CR with incomplete marrow recovery (CRi), partial response (PR), PR with lymphocytosis (PR-L), and nodular PR |
Up to approximately 7 years
|
|
Duration of response as determined by investigator
Zeitfenster: Up to approximately 7 years
|
Time from the date of the first response to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Progression-free survival as determined by investigator
Zeitfenster: Up to approximately 7 years
|
Time from the date of the first dose of study drug to the date of documented progressive disease or death due to any cause, whichever is earlier |
Up to approximately 7 years
|
|
Complete response rate as determined by investigator
Zeitfenster: Up to approximately 7 years
|
The percentage of participants with CR or CRi as determined according to 2018 iwCLL guidelines; includes CR + CRi for participants with CLL. |
Up to approximately 7 years
|
|
Time to response as determined by investigator
Zeitfenster: Up to approximately 7 years
|
Time from the start date of study treatment to the date of the first assessment of a response |
Up to approximately 7 years
|
|
Overall survival
Zeitfenster: Up to approximately 7 years
|
Time from the start date of study treatment to the date of death from any cause |
Up to approximately 7 years
|
|
Pharmacokinetic profile of NX-5948
Zeitfenster: Up to approximately 1 year
|
NX-5948 concentrations in blood samples |
Up to approximately 1 year
|
|
Pharmacokinetic profile of venetoclax
Zeitfenster: Up to approximately 1 year
|
Venetoclax concentrations in blood samples |
Up to approximately 1 year
|
|
Change from baseline in Global Health Status/Quality of Life on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30)
Zeitfenster: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EORTC QLQ-C30 questionnaire to assess the overall quality of life |
Baseline and up to approximately 27 months
|
|
Change from baseline in European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)
Zeitfenster: Baseline and up to approximately 27 months
|
Percentage of participants with a clinically meaningful change from baseline using the EQ-5D-5L questionnaire to assess health outcomes |
Baseline and up to approximately 27 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Study Director, Nurix Therapeutics, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Leukämie, B-Zell
- Lymphom
- Leukämie, lymphatisch
- Leukämie
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Lymphom, B-Zell
- Leukämie, lymphozytär, chronisch, B-Zell
- Aminosäuren, Peptide und Proteine
- Proteine
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Antikörper, monoklonale, murine abgeleitete
- Rituximab
- Venetoklax
- Obinutuzumab
Andere Studien-ID-Nummern
- NX-5948-203
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .